Publication: High expression of PKM2 as a poor prognosis indicator is associated with radiation resistance in cervical cancer
Authors
Zhao, Yajie ; Shen, Liangfang ; Chen, Xi ; Qian, Yujie ; Zhou, Qin ; Wang, Ying ; Li, Kai ; Liu, Miaomiao ; Zhang, Sai ; Huang, Xinqiong
item.page.secondaryauthor
item.page.director
Publisher
Universidad de Murcia. Departamento de Biología Celular e Histología
publication.page.editor
publication.page.department
DOI
10.14670/HH-11-627
item.page.type
info:eu-repo/semantics/article
Description
Abstract
Our study aimed to investigate the
association of Pyruvate Kinase isozyme type M2
(PKM2) with radiation resistance in locally advanced
cervical squamous cell carcinoma (LACSCC). We
retros-pectively reviewed 132 female patients who
received primary radiation therapy to treat LACSCC at
Federation Internationale of Gynecologie and
Obstetrigue（FIGO）stages IB-IVA. Forty-seven
patients with progression free survival (PFS) of less than
36 months were regarded to have radiation resistance.
Eighty-five patients with PFS no less than 36 months
were regarded as radiation sensitive. Using immunohistochemistry, we found that the overexpression rate of
PKM2 in radiation resistant and radiation sensitive
patients was 87.2% and 57.6%, respectively, and the
difference was statistically significant (p＜0.001). The
5-year progress free survival rates in patients with low
and high expression of PKM2 was 80.4% and 60.5%,
respectively, and the difference was statistically
significant (p=0.008). Multivariate Cox regression
analysis identified that high expression of PKM2 is an
independent negative prognostic factor in cervical cancer
patients [Hazard ratio (95% CI), 2.888 (1.347, 6.194)
p=0.006]. These results demonstrate that overexpression
of PKM2 contributes to radiation resistance and acts a
poor prognosis indicator in patients with LACSCC.
publication.page.subject
Citation
Histology and Histopathology, vol. 30, nº 11, (2015)
item.page.embargo
Ir a Estadísticas
Este ítem está sujeto a una licencia Creative Commons. http://creativecommons.org/licenses/by-nc-nd/3.0/es/